Pharma News

In a groundbreaking study, a team led by Würzburg Professor José Pedro Friedmann Angeli has shown that the cholesterol precursor 7-dehydrocholesterol (7-DHC) plays a crucial role as an antioxidant: it integrates into the cell membranes and protects the cells by preventing a certain type of cell death, known as ferroptosis.

Zydus Lifesciences Ltd., a global innovation driven healthcare company announced that it has launched Relugolix under the brand name, Rexigo™. This is the first and only oral once-a-day therapy for testosterone suppression in patients with advanced prostate cancer in India. Though Relugolix was available in developed countries since the last four years, patients in India did not have access to it. With this launch, Zydus brings both access to a critical therapy and also makes it affordable at a cost of Rs.

Pfizer and Glenmark Pharmaceuticals Ltd have joined hands to launch abrocitinib, a first of its kind oral advanced systemic treatment for moderate‐to‐severe atopic dermatitis (AD), in India. Developed by Pfizer, abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India and is approved by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other regulatory agencies.

Medtech giant Siemens Healthineers has teamed up with the Indian Institute of Science (IISc) to launch a collaborative laboratory in Bangalore focused on AI in precision medicine. Healthineers will invest 10 million INR in the partnership over the next five years.

HPCI Exhibition & Conference 2024 was held on 18 and 19 January, 2024 at Jio World Convention Centre, BKC, Mumbai. It was organised by ExpoNova Exhibitions & Conferences (India) Pvt. Ltd. It is the only event in India focused on raw materials and techniques for the formulation of cosmetic and cleaning products. It is indeed a place where industry meets, discovers new ingredient and technology, learns about various innovation. Companies from all over India as well as overseas participated and there was something for everyone.

Sanofi and Inhibrx, Inc. a publicly traded clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates, have entered into a definitive agreement under which Sanofi has agreed to acquire Inhibrx following the spin-off of non-INBRX-101 assets into New Inhibrx. INBRX-101 is a human recombinant protein that holds the promise of allowing Alpha-1 Antitrypsin Deficiency (AATD) patients to achieve normalization of serum AAT levels with less frequent (monthly vs. weekly) dosing.

Restricting calories is known to improve health and increase lifespan, but much of how it does so remains a mystery, especially in regard to how it protects the brain. Buck scientists have uncovered a role for a gene called OXR1 that is necessary for the lifespan extension seen with dietary restriction and is essential for healthy brain aging.

Sun Pharm and Taro Pharmaceutical Industries Ltd.  announced that they have entered into a definitive merger agreement in which Sun Pharma, Taro’s controlling shareholder, has agreed to acquire all of the outstanding ordinary shares of Taro other than the shares already held by Sun Pharma or its affiliates for USD 43.00 per share in cash without interest.

Sun Pharma and Bayer announced that both companies have signed an agreement to market and distribute a second brand of Finerenone in India. Finerenone, a patented medicine is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease associated with type 2 diabetes mellitus.